Cancers **2021**, 13 S1 of S10

Supplementary Materials: CRISPR/Cas9 Deletion of SOX2 Regulatory Region 2 (SRR2) Decreases SOX2 Malignant Activity in Glioblastoma

Ander Saenz-Antoñanzas, Veronica Moncho-Amor, Jaione Auzmendi-Iriarte, Alejandro Elua-Pinin, Karine Rizzoti, Robin Lovell-Badge and Ander Matheu




Figure S1. Clone2 and Clone5 sequenced and matching in genomic human sequence of SRR2. SRR2 (200bp) is marked by a green box. The location of the external (guide 7_5′ and guide 3_3′) and internal (guide 5_5′ and guide 1_3′) sgRNAs (orange box) is labelled including their PAM sequence (in yellow). Sequence of the Clone2 (grey box) and Clone5 (magenta box) cell lines carrying SRR2 deletion represented from sequencing. The breakpoint is shown above the colourful squares that indicate the nucleotides remained from each clone sequence following the deletion.




Figure S2. Ectopic expression of SOX2 rescues stem cell activity in SRR2 deleted cells. A) Representative images (scale bar=200 μ m) and B) volume of primary oncospheres derived from control, clone2 and clone5 cells with ectopic expression of SOX2 compared to GFP control, clone2 and clone5 cells and secondary oncospheres obtained after disaggregation of primary oncospheres. (n=4).






Figure S3. A) Expression of p53 in *SRR2* deleted GBM cells. Representative immunoblots of p53, p21^{CIP1} and SOX2 in U373MG control and U373MG *SRR2*^{del} clone2 and clone5 cells. **B)** Quantification of p53 expression in GBM cells (n=3).

Figure 1










Figure 2










Figure 4









Figure 5







Figure 5








Figure S4. Uncropped Western Blots.

Table S1. Primers for CRISPR genome editing			
sgRNA	Primer name	Sequence 5' to 3' (20-mer sgRNA recognition sequences in bold)	
GUIDE 7 UPSTREAM SRR2	G7 UP SSR2_F	5' CACC GCT TTG TTT TAG ATA TGT AC 3'	
	G7 UP SSR2_R	5' AAACGTACATATCTAAAACAAAGC 3'	
GUIDE 5 UPSTREAM SRR2	G5 UP SRR2_F:	5' CACC GGA TAA CAT TGT ACT GGG AA 3'	
	G5 UP SRR2_R:	5' AAACTTCCCAGTACAATGTTATCC 3'	
GUIDE 1 DOWNSTREAM SRR2	G1 DOWN SSR2_F	5' CACCG CCA CAG GGT CAG CAA CTT TC 3'	
	G1 DOWN SSR2_R	5' AAACGAAAGTTGCTGACCCTGTGGC 3'	
GUIDE 3 DOWNSTREAM SRR2	G3 DOWN SRR2_F:	5' CACC GGA AAG GGA GCA CAA TAT TT 3'	
	G3 DOWN SRR2_R:	5' AAAC AAATATTGTGCTCCCTTTCC3'	
pX330 plasmid	uniR	AAAAGCACCGACTCGGTGCC	

Table S2. Primers used for Genotyping and ChIP assay			
Primer name	Sequence 5' to 3'	Application	
Sox2-SRR2-F	5' ATTTATTCAGTTCCCAGTCCAAGC 3'	qPCR after ChIP	
Sox2-SRR2-R	5' CCCTCTCCCCCACGC 3'	qPCR after ChIP	
SRR2_FORWARD	5' GCCACTAAGTTAGCTCATCC 3'	Genotyping	
SSR2_REVERSE	5' ATATGAAGGGGTAGAAGGGG 3'	Genotyping	